Cover Image
市場調查報告書

次世代定序:新的臨床應用及全球市場

Next Generation Sequencing: Emerging Clinical Applications and Global Markets

出版商 BCC Research 商品編碼 276316
出版日期 內容資訊 英文 289 Pages
訂單完成後即時交付
價格
Back to Top
次世代定序:新的臨床應用及全球市場 Next Generation Sequencing: Emerging Clinical Applications and Global Markets
出版日期: 2015年06月29日 內容資訊: 英文 289 Pages
簡介

全球次世代定序 (NGS) 市場,2014年為8億8,610萬美金。預計該市場今後以31.3%的年複合成長率推移,從2015年的9億9,710萬美元到2020年擴大到39億美元。

本報告提供全球次世代定序市場與其新臨床應用市場的相關調查、含實際成果、估計資料及年複合成長率預測的世界市場趨勢分析、主要的市場區隔的產業結構調查、策略性聯盟、收購及定序專利的評估、主要企業的策略的分析及主要製造商簡介等彙整資料,為您概述為以下內容。

第1章 簡介

第2章 摘要整理

第3章 概要

  • 簡介
  • 臨床之次世代定序 (NGS) 市場
  • 臨床之次世代定序促進成長要素
    • 技術促進要素
    • 推動市場的要素
  • 臨床之次世代定序的應用
  • 臨床之次世代定序產業

第4章 技術

  • DNA的重要性
  • 遺傳的變異、分析
  • 遺傳分析技術
  • 臨床應用的次世代定序
  • 次世代定序技術
  • 未來的技術課題

第5章 臨床之次世代定序倡議的前10名

  • ACTIONABLE GENOME CONSORTIUM
  • BABYSEQ
  • CANCER MOON SHOTS PROGRAM
  • CLINGEN
  • LUNG-MAP
  • MATCHMAKER EXCHANGE
  • MILLION VETERAN PROGRAM
  • MEDSEQ
  • PRECISION MEDICINE
  • PROMPT

第6章 臨床之次世代定序應用

  • 簡介
  • 癌症應用
  • 孟德爾性疾病應用
  • 生殖健康應用
  • 感染疾病應用
  • 複合疾病應用

第7章 臨床之次世代定序產業

  • 簡介
  • 次世代定序設備產業
  • 次世代定序標的改良產業
  • 次世代定序臨床資訊學產業
  • 臨床實驗室產業
  • 印度臨床定序產業
  • 生殖健康診斷產業
  • 液體細胞診斷產業
  • 人類白細胞抗原分型診斷(HLA型檢測產業
  • 免疫定序產業
  • 次世代定序遺傳基因融合診斷產業
  • 臨床之次世代定序產業的收購、策略性聯盟

第8章 次世代定序診斷市場

  • 促進成長要素
  • 全球次世代定序診斷市場
    • 次世代定序的癌症診斷市場
    • 次世代定序的心血管診斷市場
    • 次世代定序的孟德爾性疾病診斷市場
    • 次世代定序的代謝、免疫疾病診斷市場
    • 次世代定序的神經診斷市場
    • 次世代定序的生殖健康診斷市場
    • 次世代定序的食物中毒診斷市場
    • 次世代定序的人類白細胞抗原分型診斷 (HLA型檢測診斷)市場
  • 次世代定序診斷市場:各地區
    • 北美
    • 歐洲
    • 中國
    • 日本
    • 其他

第9章 專利

  • 臨床之次世代定序專利
    • 臨床之次世代定序專利:各適應症

第10章 企業簡介

圖表清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BIO126B

The global clinical next-generation sequencing (NGS) market was valued at $886.1 million in 2014. This market is expected to grow at a compound annual growth rate (CAGR) of 31.3%, from $997.1 million in 2015 to nearly $3.9 billion by 2020.

This report provides:

  • An overview of the global market for next-generation sequencing and its emerging clinical applications.
  • Analyses of global market trends, with data from 2014, estimates for 2015, and projections of CAGRs through 2020.
  • Examination of the sequencing industry structure for key market segments.
  • Discussion covering the strategies employed by the main companies in the market.
  • Comprehensive company profiles of major players in the field.

image1

REPORT SCOPE

SCOPE AND FORMAT

The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents and companies. The markets for NGS-based diagnostics are given for the years 2014, 2015 and 2020.

This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing. It then discusses some of the top research initiatives that are contributing to clinical NGS applications. Market driving forces are also discussed.

The report examines the markets by test complexity, indication and test purpose. Test complexity refers to the multiplexing (e.g., the number of genes covered) and coverage (e.g., the extent to which the genome is covered) of the test. Examining the market by test complexity provides valuable insight into which products (e.g., sample preparation, NGS instrument, informatics) will be in demand in the future.

The report provides market data and forecasts for NGS diagnostics by specific applications, including those for cancer, rare diseases, complex disorders and reproductive health.

Specific geographic markets are discussed, including North America, Europe, China, Japan and the rest of the world.

Market data covers the years 2014, 2015 and 2020.

Industry sectors analyzed include NGS instruments, target enrichment, informatics, clinical laboratory testing services, reproductive health diagnostics, HLA typing, liquid biopsy, immune sequencing and fusion diagnostics.

More than 170 companies in the clinical NGS industry are profiled in this report.

BCC Research provides a summary of the main industry acquisitions and strategic alliances from 2013 through 2015, including key alliance trends.

ANALYST'S CREDENTIALS

John Bergin has written previous BCC Research biotechnology reports, including Proteomics: Technologies and Global Markets; Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics; Global Biochip Markets: Microarrays and Lab-on-a-chip; RNA Interference in the Post-Genomic Era: Markets and Technologies; DNA Sequencing: Emerging Technologies and Applications; Biologic Imaging Reagents: Technologies and Global Markets; and Synthetic Biology: Emerging Global Markets. Mr. Bergin has held business development, sales and marketing positions with a Fortune 500 advanced materials company, as well as executive management positions with an emerging nanotechnology company. Mr. Bergin holds a BS in Chemistry, an MS in Biotechnology and a Master of Business Administration.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • CONTRIBUTION OF THE STUDY AND INTENDED AUDIENCE
  • SCOPE AND FORMAT
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 EXECUTIVE SUMMARY

  • SUMMARY TABLE GLOBAL CLINICAL NEXT-GENERATION SEQUENCING MARKET BY DISEASE CLASS, THROUGH 2020 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL CLINICAL NEXT-GENERATION SEQUENCING MARKET BY DISEASE CLASS, 2014-2020 ($ MILLIONS)

CHAPTER 3 OVERVIEW

  • INTRODUCTION
  • TABLE 1 REPORT SCOPE
  • CLINICAL NGS MARKETS
  • TABLE 2 GLOBAL NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY DISEASE TYPE, THROUGH 2020 ($ MILLIONS)
  • CLINICAL NGS GROWTH DRIVING FORCES
    • TECHNOLOGY DRIVERS
    • TABLE 3 KEY TECHNOLOGY DRIVERS FOR CLINICAL NEXT-GENERATION SEQUENCING
    • MARKET DRIVERS
    • TABLE 4 CLINICAL NEXT-GENERATION SEQUENCING MARKET DRIVING FORCES
  • CLINICAL NGS APPLICATIONS
  • TABLE 5 CLINICAL NEXT-GENERATION SEQUENCING APPLICATION STATUS
  • CLINICAL NGS INDUSTRY
  • TABLE 6 KEY DIAGNOSTIC NEXT-GENERATION SEQUENCING INDUSTRY PARTICIPANTS BY SECTOR

CHAPTER 4 TECHNOLOGIES

  • IMPORTANCE OF DNA
  • TABLE 7 DNA CHEMICAL BUILDING BLOCKS
  • TABLE 8 DNA TRANSLATION AND TRANSCRIPTION
  • TABLE 9 LONG-RANGE DNA STRUCTURE
  • GENETIC VARIATION AND ANALYSIS
  • TABLE 10 GENETIC VARIANT TYPES
  • GENETIC ANALYSIS TECHNOLOGIES
  • TABLE 11 IMPORTANT MOLECULAR DIAGNOSTIC PLATFORMS
  • NGS IN CLINICAL APPLICATIONS
  • TABLE 12 GENETIC TESTING EVOLUTION
  • TABLE 13 MARKET SEGMENTS FOR NEXT-GENERATION SEQUENCING DIAGNOSTICS
  • NGS TECHNOLOGIES
    • HISTORY OF DNA SEQUENCING
    • TABLE 14 DNA SEQUENCING HISTORICAL TIMELINE, 1977-2015
    • TABLE 15 SEQUENCING TECHNOLOGY DEVELOPMENT, 1990-2020
    • FIGURE 1 EFFECT OF NEW SEQUENCING TECHNOLOGIES ON COST TO SEQUENCE A SINGLE HUMAN GENOME, 2001-2014 [3] ($/GENOME)
    • SANGER SEQUENCING TECHNOLOGY 3
    • TABLE 16 SANGER SEQUENCING SUMMARY
    • TABLE 17 SANGER SEQUENCING IMPROVEMENTS
    • NGS PLATFORMS
    • TABLE 18 NEXT-GENERATION SEQUENCING TECHNOLOGIES
    • TABLE 19 ROCHE NEXT-GENERATION SEQUENCING WORKFLOW
    • TABLE 20 ILLUMINA NEXT-GENERATION SEQUENCING WORKFLOW
    • TABLE 21 LIFE TECHNOLOGIES NEXT-GENERATION SEQUENCING WORKFLOW
    • BENCHTOP SEQUENCERS
    • TABLE 22 BENCHTOP SEQUENCER PLATFORMS
    • NANOPORE SEQUENCING TECHNOLOGIES
    • INFORMATICS TECHNOLOGIES
    • TABLE 23 NEXT-GENERATION SEQUENCING BIOINFORMATICS WORKFLOW
    • BASE CALLING
    • MAPPING TO A REFERENCE SEQUENCE
    • TABLE 24 SEQUENCE ANNOTATION STEPS
    • VARIANT ANALYSIS
  • FUTURE TECHNOLOGY CHALLENGES
  • TABLE 25 FUTURE CHALLENGES FOR IMPLEMENTING CLINICAL NEXT-GENERATION SEQUENCING

CHAPTER 5 TOP 10 CLINICAL NGS INITIATIVES

  • TABLE 26 TOP 10 CLINICAL NEXT-GENERATION SEQUENCING PROJECTS
  • ACTIONABLE GENOME CONSORTIUM
  • BABYSEQ
  • CANCER MOON SHOTS PROGRAM
  • CLINGEN
  • LUNG-MAP
  • MATCHMAKER EXCHANGE
  • MILLION VETERAN PROGRAM
  • MEDSEQ
  • PRECISION MEDICINE
  • PROMPT

CHAPTER 6 CLINICAL NGS APPLICATIONS

  • INTRODUCTION
  • TABLE 27 CLINICAL NEXT-GENERATION SEQUENCING, NEAR TO MID-TERM APPLICATIONS
  • CANCER APPLICATIONS
  • TABLE 28 CANCER APPLICATIONS
  • MENDELIAN DISORDERS APPLICATIONS
  • TABLE 29 MENDELIAN DISORDERS APPLICATIONS
  • REPRODUCTIVE HEALTH APPLICATIONS
  • TABLE 30 SCREENING APPLICATIONS
  • TABLE 31 ETHICAL ISSUES ASSOCIATED WITH PRENATAL AND NEWBORN SCREENING
  • INFECTIOUS DISEASE APPLICATIONS
  • TABLE 32 INFECTIOUS DISEASE APPLICATIONS
  • COMPLEX DISORDERS APPLICATIONS
  • TABLE 33 COMPLEX DISORDER APPLICATIONS

CHAPTER 7 CLINICAL NGS INDUSTRY

  • INTRODUCTION
  • TABLE 34 KEY SEGMENTS WITHIN THE NEXT-GENERATION SEQUENCING CLINICAL INDUSTRY
  • NGS INSTRUMENT INDUSTRY
  • TABLE 35 NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES SUMMARY
  • NGS TARGET ENRICHMENT INDUSTRY
  • TABLE 36 NEXT-GENERATION SEQUENCING-BASED TARGET ENRICHMENT INDUSTRY
  • NGS CLINICAL INFORMATICS INDUSTRY
  • TABLE 37 NEXT-GENERATION SEQUENCING CLINICAL INFORMATICS COMPANY POSITIONING
  • NGS CLINICAL LABORATORY TESTING SERVICES INDUSTRY
  • TABLE 38 NGS CLINICAL LABORATORY TESTING SERVICES INDUSTRY
  • INDIA'S CLINICAL SEQUENCING INDUSTRY
  • TABLE 39 INDIA NGS CLINICAL SEQUENCING COMPETITIVE POSITIONING
  • REPRODUCTIVE HEALTH DIAGNOSTICS INDUSTRY
    • NONINVASIVE PRENATAL TESTING INDUSTRY
    • TABLE 40 NGS NIPT INDUSTRY
    • TABLE 41 GLOBAL NGS-BASED NONINVASIVE PRENATAL DIAGNOSTIC MARKET SHARE BY TEST, 2014 (%)
    • TABLE 42 GERMANY NGS-BASED NONINVASIVE PRENATAL DIAGNOSTIC COMPETITIVE SITUATION
    • PREIMPLANTATION GENETICS DIAGNOSIS/SCREENING INDUSTRY
    • TABLE 43 PREIMPLANTATION DIAGNOSTICS PLATFORMS
    • TABLE 44 PREIMPLANTATION GENETIC SCREENING AND DIAGNOSIS INDUSTRY
  • LIQUID BIOPSY INDUSTRY
  • TABLE 45 NGS-BASED LIQUID BIOPSY INDUSTRY
  • HLA TYPING INDUSTRY
  • TABLE 46 NGS-BASED HLA TYPING INDUSTRY COMPETITORS
  • IMMUNE SEQUENCING INDUSTRY
  • TABLE 47 IMMUNE SYSTEM PROFILING INDUSTRY
  • NGS GENE FUSION DIAGNOSTICS INDUSTRY
  • TABLE 48 NGS-BASED GENE FUSION DIAGNOSTICS INDUSTRY
  • CLINICAL NGS INDUSTRY ACQUISITIONS AND STRATEGIC ALLIANCES
    • ACQUISITIONS
    • TABLE 49 CLINICAL NEXT-GENERATION SEQUENCING INDUSTRY ACQUISITIONS, 2013- MARCH 2015
    • STRATEGIC ALLIANCES
    • TABLE 50 CLINICAL NEXT-GENERATION SEQUENCING STRATEGIC ALLIANCES, 2013-MARCH 2015

CHAPTER 8 NGS DIAGNOSTICS MARKETS

  • GROWTH DRIVING FORCES
  • TABLE 51 CLINICAL NEXT-GENERATION SEQUENCING KEY GROWTH DRIVING FORCES, THROUGH 2020
  • TABLE 52 CLINICAL NGS STAKEHOLDERS ACTIVITY
  • GLOBAL NGS DIAGNOSTIC MARKET
  • TABLE 53 GLOBAL NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 ($ MILLIONS)
  • TABLE 54 GLOBAL NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 ($ MILLIONS)
    • NGS CANCER DIAGNOSTIC MARKETS
    • TABLE 55 GLOBAL NEXT-GENERATION SEQUENCING CANCER DIAGNOSTIC MARKET BY SEGMENT, THROUGH 2020 ($ MILLIONS)
    • TABLE 56 GLOBAL NEXT-GENERATION SEQUENCING CANCER DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 ($ MILLIONS)
      • NGS Cancer Diagnosis Market
      • NGS Cancer Screening Market
      • NGS Cancer Monitoring Market
      • NGS Cancer Therapy Guidance Market
      • Companion Diagnostics
      • TABLE 57 RECENT NGS-BASED COMPANION DIAGNOSTICS ACTIVITIES
      • Thyroid and Leukemia Update
    • NGS Cancer Market by Test Complexity
    • TABLE 58 GLOBAL CANCER NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 ($ MILLIONS)
    • TABLE 59 MULTI-GENE NGS-BASED HEMATOLOGICAL TESTS
    • NGS CARDIOLOGY DIAGNOSTIC MARKETS
    • TABLE 60 GLOBAL NEXT-GENERATION SEQUENCING CARDIOVASCULAR DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 ($ MILLIONS)
    • TABLE 61 DILATED CARDIOMYOPATHY TEST PROVIDERS
    • TABLE 62 GLOBAL NEXT-GENERATION SEQUENCING CARDIOLOGY DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 ($ MILLIONS)
    • NGS MENDELIAN DISORDERS DIAGNOSTIC MARKETS
    • TABLE 63 GLOBAL NEXT-GENERATION SEQUENCING MENDELIAN DISORDER DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 ($ MILLIONS)
    • TABLE 64 GLOBAL NEXT-GENERATION SEQUENCING MENDELIAN DISORDER DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 ($ MILLIONS)
    • NGS METABOLIC/IMMUNE DISORDER DIAGNOSTIC MARKETS 145
    • TABLE 65 GLOBAL NEXT-GENERATION SEQUENCING METABOLIC AND IMMUNE DISORDER DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 ($ MILLIONS)
    • TABLE 66 MULTIPLE SCLEROSIS DIAGNOSTIC TECHNOLOGIES
    • TABLE 67 GLOBAL NEXT-GENERATION SEQUENCING METABOLIC AND IMMUNE DISORDER DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 ($ MILLIONS)
    • NGS NEUROLOGY DIAGNOSTIC MARKETS
    • TABLE 68 GLOBAL NEXT-GENERATION SEQUENCING NEUROLOGY DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 ($ MILLIONS)
    • TABLE 69 GLOBAL NEXT-GENERATION SEQUENCING NEUROLOGY DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 ($ MILLIONS)
    • NGS REPRODUCTIVE HEALTH DIAGNOSTIC MARKETS
      • Newborn Screening Diagnostic Market
      • TABLE 70 GLOBAL NEXT-GENERATION SEQUENCING NEWBORN SCREENING DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 ($ MILLIONS)
      • TABLE 71 GLOBAL NEXT-GENERATION SEQUENCING NEWBORN SCREENING DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 ($ MILLIONS)
      • Prenatal Screening Diagnostic Market 153
      • TABLE 72 GLOBAL NEXT-GENERATION SEQUENCING PRENATAL DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 ($ MILLIONS)
      • TABLE 73 GLOBAL NEXT-GENERATION SEQUENCING PRENATAL DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 ($ MILLIONS)
      • Preimplantation Diagnostic Market
      • TABLE 74 GLOBAL NEXT-GENERATION SEQUENCING PREIMPLANTATION DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 ($ MILLIONS)
      • TABLE 75 GLOBAL NEXT-GENERATION SEQUENCING PREIMPLANTATION DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 ($ MILLIONS)
    • NGS FOOD-BORNE ILLNESS DIAGNOSTIC MARKET
    • TABLE 76 GLOBAL NEXT-GENERATION SEQUENCING FOOD-BORNE ILLNESS DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 ($ MILLIONS)
    • TABLE 77 GLOBAL NEXT-GENERATION SEQUENCING FOOD-BORNE ILLNESS DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 ($ MILLIONS)
    • TABLE 78 NGS IN INFECTIOUS DISEASE DIAGNOSTICS
    • NGS HLA TYPING DIAGNOSTIC MARKET
    • TABLE 79 GLOBAL NEXT-GENERATION SEQUENCING HLA TYPING DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 ($ MILLIONS)
    • TABLE 80 GLOBAL NEXT-GENERATION SEQUENCING HLA TYPING DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 ($ MILLIONS)
    • NGS DIAGNOSTIC MARKETS BY REGION
    • TABLE 81 GLOBAL NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
    • NORTH AMERICA
    • TABLE 82 NORTH AMERICAN NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
    • EUROPE
    • TABLE 83 EUROPEAN NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
    • CHINA
    • TABLE 84 CHINA NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
    • JAPAN
    • TABLE 85 JAPANESE NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
    • REST OF WORLD
    • TABLE 86 REST OF WORLD NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)

CHAPTER 9 PATENTS

  • CLINICAL NGS PATENTS
  • TABLE 87 CLINICAL NEXT-GENERATION SEQUENCING PATENTS, 2004-2014
    • CLINICAL NGS PATENTS BY INDICATION
    • TABLE 88 CLINICAL NEXT-GENERATION SEQUENCING PATENTS BY INDICATION, 2004-2014
    • STATUS OF MYRIAD'S BRCA PATENTS
    • SEQUENOM AND ILLUMINA NIPT PATENT POOL

CHAPTER 10 COMPANY PROFILES

  • 10X GENOMICS
  • 14M GENOMICS LTD.
  • 23ANDME INC.
  • TABLE 89 DATA NEEDS
  • ADAPTIVE BIOTECHNOLOGIES INC.
  • ADMERA HEALTH
  • AGILENT TECHNOLOGIES INC.
  • ALMAC GROUP LTD.
  • AMARANTUS BIOSCIENCE HOLDINGS INC.
  • AMBRY GENETICS
  • APPISTRY INC.
  • ARUP LABORATORIES
  • ASSUREX HEALTH
  • ASTRIDBIO TECHNOLOGIES KFT.
  • ASURAGEN INC.
  • ATHENA DIAGNOSTICS INC.
  • ATRECA INC.
  • BASE4 INNOVATION LTD.
  • BAYLOR MIRACA GENETICS LABORATORIES INC.
  • BECTON, DICKINSON AND CO.
  • BERRY GENOMICS CO. LTD.
  • BGI SHENZHEN
  • BIOARRAY SL
  • BIODESIX INC.
  • BIOINNOVATION SOLUTIONS SA
  • BIO-RAD LABORATORIES INC.
  • BIOTHERANOSTICS INC.
  • BLUEPRINT GENETICS
  • BOREAL GENOMICS
  • CAREDX INC.
  • CARIS LIFE SCIENCES
  • CEGAT GMBH
  • CELLULAR RESEARCH INC.
  • CENTOGENE AG
  • CERGENTIS BV
  • CHRONIX BIOMEDICAL
  • CLARITAS GENOMICS INC.
  • CLEVELAND CLINICAL LABORATORIES
  • COFACTOR GENOMICS INC.
  • CORIELL LIFE SCIENCES INC.
  • CORRELAGEN DIAGNOSTICS INC.
  • COUNSYL INC.
  • COURTAGEN LIFE SCIENCES INC.
  • CYNVENIO BIOSYSTEMS INC.
  • CYPHER GENOMICS INC.
  • DANAHER CORP.
  • DIPLOID
  • DIRECTED GENOMICS LLC
  • DNA ELECTRONICS LTD.
  • DNA LINK INC.
  • DNANEXUS INC.
  • ELECTRONIC BIOSCIENCES
  • ESPERITE NV
  • EUROFINS GENOMICS
  • EXOSOME DIAGNOSTICS INC.
  • EXPRESSION ANALYSIS INC.
  • FOUNDATION MEDICINE 214
  • FUSION GENOMICS CORP.
  • GATC BIOTECH AG
  • GE HEALTHCARE
  • GENAPSYS INC.
  • GENDX BV
  • GENE BY GENE LTD.
  • GENEDX INC.
  • GENEPEEKS INC.
  • GENOLOGICS LIFE SCIENCES SOFTWARE
  • GENOMATIX SOFTWARE GMBH
  • GENOMEDX
  • GENOMEQUEST INC.
  • GENOMIC EXPRESSION
  • GENOMIC HEALTH INC.
  • GENOMONCOLOGY
  • GENOSPACE
  • GIGAGEN INC.
  • GOLDEN HELIX
  • GOOD START GENETICS INC.
  • HISTOGENETICS LLC
  • HTG MOLECULAR DIAGNOSTICS INC.
  • ILLUMINA INC.
  • TABLE 90 NEW PLATFORMS INTRODUCED BY ILLUMINA IN 2015
  • INNOVATIONS EXCHANGE PTE. LTD.
  • INTELLIMEDIX
  • INTERPACE DIAGNOSTICS LLC
  • INVITAE
  • INVIVOSCRIBE TECHNOLOGIES INC.
  • IREPERTOIRE INC.
  • KAILOS GENETICS
  • KELLBENX INC.
  • KEW GROUP INC.
  • KNOME INC.
  • LABORATORY CORPORATION OF AMERICA INC.
  • LABORATORY FOR MOLECULAR MEDICINE
  • LASERGEN INC.
  • LEUCINE RICH BIO
  • LIFECODE INC.
  • LUMENOGIX INC.
  • MACROGEN INC.
  • MAVERIX BIOMICS INC.
  • MAYO MEDICAL LABORATORIES
  • MEDGENOME LABS PVT. LTD.
  • MEDICAL DIAGNOSTIC LABORATORIES LLC
  • MEDOMICS LLC
  • MERCK KGAA
  • MIRATI THERAPEUTICS
  • MOGENE CLINICAL DIAGNOSTICS
  • MOLECULAR HEALTH GMBH
  • MOLECULARMD CORP.
  • MRIGLOBAL RESEARCH INSTITUTE
  • MULTIPLICOM NV
  • MYRIAD GENETICS INC.
  • NABSYS INC.
  • NANTHEALTH
  • NATERA INC.
  • NEOGENOMICS INC.
  • NEW ENGLAND BIOLABS
  • NEWGENE LTD.
  • NEW ONCOLOGY AG
  • N-OF-ONE INC.
  • NOVARTIS AG
  • NUGEN TECHNOLOGIES INC.
  • OMICIA INC.
  • OMIXON BIOCOMPUTING KFT
  • ONCODNA SA
  • OXFORD GENE TECHNOLOGY
  • OXFORD NANOPORE TECHNOLOGIES LTD.
  • PACIFIC BIOSCIENCES OF CALIFORNIA INC.
  • PARABASE GENOMICS
  • PARSEQ LAB
  • PATHOGENETIX
  • PATHWAY GENOMICS .
  • PERKINELMER INC.
  • PERSONAL GENOME DIAGNOSTICS INC.
  • PERSONAL GENOMICS INC.
  • PERSONALIS INC.
  • PICOSEQ
  • POPULATION GENETICS TECHNOLOGIES LTD.
  • TABLE 91 SENSITIVITY TO DETECT DRUG RESISTANT MUTATIONS IN VIRUSES (%)
  • PORTABLE GENOMICS LLC
  • PREMAITHA HEALTH PLC
  • PRENETICS
  • PRESSURE BIOSCIENCES INC.
  • PREVENTIONGENETICS INC.
  • QIAGEN NV
  • QUANTAPORE INC.
  • QUANTUMDX GROUP
  • QUEST DIAGNOSTICS
  • RAINDANCE TECHNOLOGIES INC.
  • REAL TIME GENOMICS INC.
  • REPROGENETICS
  • RESPONSE GENETICS INC.
  • ROCHE HOLDING AG
  • TABLE 92 COMMERCIAL SEQUENCER COMPETITIVE POSITIONING
  • ROSWELL PARK CANCER INSTITUTE
  • SCIGENOM LABS
  • SELAH GENOMICS
  • SENGENICS INTERNATIONAL PTE LTD.
  • SEQUENOM INC.
  • SEVEN BRIDGES GENOMICS INC.
  • SISTEMAS GENOMICOS SL
  • SOFTGENETICS LLC
  • SOPHIA GENETICS
  • STATION X INC.
  • STRAND LIFE SCIENCES
  • STRATOS GENOMICS INC.
  • SUNDANCE DIAGNOSTICS INC.
  • SUPRATECH MICROPATH LABORATORY & RESEARCH INSTITUTE
  • SYAPSE
  • SYMBIODX
  • THERMO FISHER SCIENTIFIC INC.
  • TRANSGENOMIC INC.
  • TROVAGENE INC.
  • VELA DIAGNOSTICS
  • WAFERGEN BIOSYSTEMS INC.
  • TABLE 93 WAFERGEN STRATEGIC ALLIANCES
  • WARP DRIVE BIO LLC
  • YIKON GENOMICS CO. LTD.
  • ZS GENETICS INC.

LIST OF TABLES

  • SUMMARY TABLE GLOBAL CLINICAL NEXT-GENERATION SEQUENCING MARKET BY DISEASE CLASS, THROUGH 2020 ($ MILLIONS)
  • TABLE 1 REPORT SCOPE
  • TABLE 2 GLOBAL NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY DISEASE TYPE, THROUGH 2020 ($ MILLIONS)
  • TABLE 3 KEY TECHNOLOGY DRIVERS FOR CLINICAL NEXT-GENERATION SEQUENCING
  • TABLE 4 CLINICAL NEXT-GENERATION SEQUENCING MARKET DRIVING FORCES
  • TABLE 5 CLINICAL NEXT-GENERATION SEQUENCING APPLICATION STATUS
  • TABLE 6 KEY DIAGNOSTIC NEXT-GENERATION SEQUENCING INDUSTRY PARTICIPANTS BY SECTOR
  • TABLE 7 DNA CHEMICAL BUILDING BLOCKS
  • TABLE 8 DNA TRANSLATION AND TRANSCRIPTION
  • TABLE 9 LONG-RANGE DNA STRUCTURE
  • TABLE 10 GENETIC VARIANT TYPES
  • TABLE 11 IMPORTANT MOLECULAR DIAGNOSTIC PLATFORMS
  • TABLE 12 GENETIC TESTING EVOLUTION
  • TABLE 13 MARKET SEGMENTS FOR NEXT-GENERATION SEQUENCING DIAGNOSTICS
  • TABLE 14 DNA SEQUENCING HISTORICAL TIMELINE, 1977-2015
  • TABLE 15 SEQUENCING TECHNOLOGY DEVELOPMENT, 1990-2020
  • TABLE 16 SANGER SEQUENCING SUMMARY
  • TABLE 17 SANGER SEQUENCING IMPROVEMENTS
  • TABLE 18 NEXT-GENERATION SEQUENCING TECHNOLOGIES
  • TABLE 19 ROCHE NEXT-GENERATION SEQUENCING WORKFLOW
  • TABLE 20 ILLUMINA NEXT-GENERATION SEQUENCING WORKFLOW
  • TABLE 21 LIFE TECHNOLOGIES NEXT-GENERATION SEQUENCING WORKFLOW
  • TABLE 22 BENCHTOP SEQUENCER PLATFORMS 4
  • TABLE 23 NEXT-GENERATION SEQUENCING BIOINFORMATICS WORKFLOW
  • TABLE 24 SEQUENCE ANNOTATION STEPS
  • TABLE 25 FUTURE CHALLENGES FOR IMPLEMENTING CLINICAL NEXT-GENERATION SEQUENCING
  • TABLE 26 TOP 10 CLINICAL NEXT-GENERATION SEQUENCING PROJECTS
  • TABLE 27 CLINICAL NEXT-GENERATION SEQUENCING, NEAR TO MID-TERM APPLICATIONS
  • TABLE 28 CANCER APPLICATIONS
  • TABLE 29 MENDELIAN DISORDERS APPLICATIONS
  • TABLE 30 SCREENING APPLICATIONS
  • TABLE 31 ETHICAL ISSUES ASSOCIATED WITH PRENATAL AND NEWBORN SCREENING
  • TABLE 32 INFECTIOUS DISEASE APPLICATIONS
  • TABLE 33 COMPLEX DISORDER APPLICATIONS
  • TABLE 34 KEY SEGMENTS WITHIN THE NEXT-GENERATION SEQUENCING CLINICAL INDUSTRY
  • TABLE 35 NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES SUMMARY
  • TABLE 36 NEXT-GENERATION SEQUENCING-BASED TARGET ENRICHMENT INDUSTRY
  • TABLE 37 NEXT-GENERATION SEQUENCING CLINICAL INFORMATICS COMPANY POSITIONING
  • TABLE 38 NGS CLINICAL LABORATORY TESTING SERVICES INDUSTRY
  • TABLE 39 INDIA NGS CLINICAL SEQUENCING COMPETITIVE POSITIONING
  • TABLE 40 NGS NIPT INDUSTRY
  • TABLE 41 GLOBAL NGS-BASED NONINVASIVE PRENATAL DIAGNOSTIC MARKET SHARE BY TEST, 2014 (%)
  • TABLE 42 GERMANY NGS-BASED NONINVASIVE PRENATAL DIAGNOSTIC COMPETITIVE SITUATION
  • TABLE 43 PREIMPLANTATION DIAGNOSTICS PLATFORMS
  • TABLE 44 PREIMPLANTATION GENETIC SCREENING AND DIAGNOSIS INDUSTRY
  • TABLE 45 NGS-BASED LIQUID BIOPSY INDUSTRY
  • TABLE 46 NGS-BASED HLA TYPING INDUSTRY COMPETITORS
  • TABLE 47 IMMUNE SYSTEM PROFILING INDUSTRY
  • TABLE 48 NGS-BASED GENE FUSION DIAGNOSTICS INDUSTRY
  • TABLE 49 CLINICAL NEXT-GENERATION SEQUENCING INDUSTRY ACQUISITIONS, 2013- MARCH 2015
  • TABLE 50 CLINICAL NEXT-GENERATION SEQUENCING STRATEGIC ALLIANCES, 2013-MARCH 2015
  • TABLE 51 CLINICAL NEXT-GENERATION SEQUENCING KEY GROWTH DRIVING FORCES, THROUGH 2020 19
  • TABLE 52 CLINICAL NGS STAKEHOLDERS ACTIVITY
  • TABLE 53 GLOBAL NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 ($ MILLIONS)
  • TABLE 54 GLOBAL NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 ($ MILLIONS)
  • TABLE 55 GLOBAL NEXT-GENERATION SEQUENCING CANCER DIAGNOSTIC MARKET BY SEGMENT, THROUGH 2020 ($ MILLIONS)
  • TABLE 56 GLOBAL NEXT-GENERATION SEQUENCING CANCER DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 ($ MILLIONS)
  • TABLE 57 RECENT NGS-BASED COMPANION DIAGNOSTICS ACTIVITIES
  • TABLE 58 GLOBAL CANCER NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 ($ MILLIONS)
  • TABLE 59 MULTI-GENE NGS-BASED HEMATOLOGICAL TESTS
  • TABLE 60 GLOBAL NEXT-GENERATION SEQUENCING CARDIOVASCULAR DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 ($ MILLIONS)
  • TABLE 61 DILATED CARDIOMYOPATHY TEST PROVIDERS
  • TABLE 62 GLOBAL NEXT-GENERATION SEQUENCING CARDIOLOGY DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 ($ MILLIONS)
  • TABLE 63 GLOBAL NEXT-GENERATION SEQUENCING MENDELIAN DISORDER DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 ($ MILLIONS)
  • TABLE 64 GLOBAL NEXT-GENERATION SEQUENCING MENDELIAN DISORDER DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 ($ MILLIONS)
  • TABLE 65 GLOBAL NEXT-GENERATION SEQUENCING METABOLIC AND IMMUNE DISORDER DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 ($ MILLIONS)
  • TABLE 66 MULTIPLE SCLEROSIS DIAGNOSTIC TECHNOLOGIES
  • TABLE 67 GLOBAL NEXT-GENERATION SEQUENCING METABOLIC AND IMMUNE DISORDER DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 ($ MILLIONS)
  • TABLE 68 GLOBAL NEXT-GENERATION SEQUENCING NEUROLOGY DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 ($ MILLIONS)
  • TABLE 69 GLOBAL NEXT-GENERATION SEQUENCING NEUROLOGY DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 ($ MILLIONS)
  • TABLE 70 GLOBAL NEXT-GENERATION SEQUENCING NEWBORN SCREENING DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 ($ MILLIONS)
  • TABLE 71 GLOBAL NEXT-GENERATION SEQUENCING NEWBORN SCREENING DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 ($ MILLIONS)
  • TABLE 72 GLOBAL NEXT-GENERATION SEQUENCING PRENATAL DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 ($ MILLIONS)
  • TABLE 73 GLOBAL NEXT-GENERATION SEQUENCING PRENATAL DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 ($ MILLIONS)
  • TABLE 74 GLOBAL NEXT-GENERATION SEQUENCING PREIMPLANTATION DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 ($ MILLIONS)
  • TABLE 75 GLOBAL NEXT-GENERATION SEQUENCING PREIMPLANTATION DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 ($ MILLIONS)
  • TABLE 76 GLOBAL NEXT-GENERATION SEQUENCING FOOD-BORNE ILLNESS DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 ($ MILLIONS)
  • TABLE 77 GLOBAL NEXT-GENERATION SEQUENCING FOOD-BORNE ILLNESS DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 ($ MILLIONS)
  • TABLE 78 NGS IN INFECTIOUS DISEASE DIAGNOSTICS
  • TABLE 79 GLOBAL NEXT-GENERATION SEQUENCING HLA TYPING DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2020 ($ MILLIONS)
  • TABLE 80 GLOBAL NEXT-GENERATION SEQUENCING HLA TYPING DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2020 ($ MILLIONS)
  • TABLE 81 GLOBAL NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 82 NORTH AMERICAN NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 83 EUROPEAN NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 84 CHINA NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 85 JAPANESE NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 86 REST OF WORLD NEXT-GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 87 CLINICAL NEXT-GENERATION SEQUENCING PATENTS, 2004-2014
  • TABLE 88 CLINICAL NEXT-GENERATION SEQUENCING PATENTS BY INDICATION, 2004-2014
  • TABLE 89 DATA NEEDS
  • TABLE 90 NEW PLATFORMS INTRODUCED BY ILLUMINA IN 2015
  • TABLE 91 SENSITIVITY TO DETECT DRUG RESISTANT MUTATIONS IN VIRUSES (%)
  • TABLE 92 COMMERCIAL SEQUENCER COMPETITIVE POSITIONING
  • TABLE 93 WAFERGEN STRATEGIC ALLIANCES

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL CLINICAL NEXT-GENERATION SEQUENCING MARKET BY DISEASE CLASS, 2014-2020 ($ MILLIONS)
  • FIGURE 1 EFFECT OF NEW SEQUENCING TECHNOLOGIES ON COST TO SEQUENCE A SINGLE HUMAN GENOME, 2001-2014 [3] ($/GENOME)
Back to Top